All‐trans retinoic acid (ATRA) in non‐promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low‐dose Ara‐C in three elderly patients with <i>NPM1</i> ‐mutated AML unfit for intensive chemotherapy and review of the literature
Clinical case reports